Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volitinib in MET-amplified advanced gastric adenocarcinoma
NCT02449551Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Feb 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib in gastric adenocarcinoma, sponsored by Samsung Medical Center. Started Feb 2016; status: completed.
02
Drugs
savolitinib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02449551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02449551.